Longevity futurist Rand says “80 will be the new 40 by 2035.” It is a striking prediction. As a literal scientific forecast, though, it is not supported by current evidence.
There is real progress behind the optimism. Life Biosciences recently reported the first human data from its Phase 1 ER-100 epigenetic-restoration trial. The treatment was well tolerated through 56 days in three glaucoma participants, with preliminary visual-field improvements in two. But the company itself stresses that the trial is primarily testing safety and tolerability—not proving whole-body age reversal.
Population evidence is much more cautious. A major Nature Aging analysis found that gains in life expectancy have slowed and concluded that radical human life extension is implausible this century unless biological aging can be substantially slowed.
For an 80-year-old to be biologically comparable to a typical 40-year-old, medicine would need to preserve or restore multiple systems at once: cardiovascular function, muscle, bone, immunity, metabolism and cognition. No human therapy has demonstrated that.
BitcoinVersus.Tech has previously examined how close science is to solving aging, the first ER-100 human trial, and earlier longevity biology research.
Verdict: possible as a long-term aspiration, but not currently a valid evidence-based prediction for 2035. The next nine years could produce major breakthroughs, but Rand’s timeline remains speculative.
BitcoinVersus.Tech Editor’s Note:
We volunteer daily to ensure the credibility of the information on this platform is Verifiably True. If you would like to support to help further secure the integrity of our research initiatives, please donate using the QR code provided
For best QR-code scanning results, please scan this donation code from a desktop or larger screen. Mobile screens may prevent camera recognition.
BitcoinVersus.tech is not a financial advisor. This media platform reports on financial subjects purely for informational purposes.
Leave a Reply